TORONTO, Sept. 14, 2017 /CNW/ - Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that the company is scheduled to present an update on the company's programs and progress at several upcoming conferences.
Ladenburg Thalmann 2017 Healthcare Conference Presenter: Dr. Robert Uger, Chief Scientific Officer Date and Time: September 26, 2017 at 9:00 a.m. EDT Location: Hotel Sofitel, New York City
2017 Cantor Fitzgerald Global Healthcare Conference Presenter: Dr. Niclas Stiernholm, Chief Executive Officer Date and Time: September 26, 2017 at 2:15 p.m. EDT Location: Intercontinental Barclay Hotel, New York City
Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology Presenters: Dr. Niclas Stiernholm, Chief Executive Officer and Dr. Robert Uger, Chief Scientific Officer Date and Time: September 28, 2017 at 4:30 p.m. EDT Location: Lotte New York Palace Hotel, New York City
A live audio webcast of the Leerink Partners presentation will be available under the investor relations section of Trillium's website at www.trilliumtherapeutics.com.
Cambridge Healthtech Institute's Inaugural "Targeting Tumor Myeloid Cells" Presenter: Dr. Lisa Johnson, Research Scientist Date and Time: September 28, 2017 at 9:35 a.m. EDT Location: The Westin Copley Place, Boston
About Trillium Therapeutics
Trillium Therapeutics Inc. is a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. The company's lead program, TTI-621, is a SIRPaFc fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1). It is designed to act as a soluble decoy receptor, preventing CD47 from delivering its inhibitory ("do not eat") signal. Neutralization of the inhibitory CD47 signal enables the activation of macrophage anti-tumor effects by pro-phagocytic ("eat") signals. A Phase 1 clinical trial (NCT02663518) evaluating intravenous dosing of SIRPaFc in patients with advanced cancer is ongoing, and a second Phase 1 trial evaluating direct intratumoral injections is underway in solid tumors and mycosis fungoides (NCT02890368). TTI-622 is an IgG4 SIRPaFc protein, which is primarily being developed for combination therapy. An IND filing is targeted for 2H/17. Trillium also has a proprietary medicinal chemistry platform, using unique fluorine chemistry, which permits the creation of new chemical entities from validated drugs and drug candidates with improved pharmacological properties. Stemming from this platform, the company's most advanced preclinical program is an orally-available epidermal growth factor receptor antagonist with increased uptake and retention in the brain. In addition, a number of compounds directed at undisclosed immuno-oncology targets are currently in the discovery phase.